Genotype-Guided Dosing of Warfarin in Chinese Adults

作者
Chengxian Guo,Yun Kuang,Honghao Zhou,Hong Yuan,Qi Pei,Jingle Li,Weihong Jiang,Chee M. Ng,Xiaoping Chen,Yong Huo,Yimin Cui,Xiaobin Wang,Jingjing Yu,Xue Sun,Wanying Yu,Peng Chen,Da Miao,Wenyu Liu,Zaixin Yu,Zewei Ouyang
出处
期刊:Circulation [Wolters Kluwer]
卷期号:13 (4): e002602-e002602 被引量:23
标识
DOI:10.1161/circgen.119.002602
摘要

Background: Warfarin is an effective treatment for thromboembolic disease but has a narrow therapeutic index; optimal anticoagulation dosage can differ tremendously among individuals. We aimed to evaluate whether genotype-guided warfarin dosing is superior to routine clinical dosing for the outcomes of interest in Chinese patients. Methods: We conducted a multicenter, randomized, single-blind, parallel-controlled trial from September 2014 to April 2017 in 15 hospitals in China. Eligible patients were ≥18 years of age, with atrial fibrillation or deep vein thrombosis without previous treatment of warfarin or a bleeding disorder. Nine follow-up visits were performed during the 12-week study period. The primary outcome measure was the percentage of time in the therapeutic range of the international normalized ratio during the first 12 weeks after starting warfarin therapy. Results: A total of 660 participants were enrolled and randomly assigned to a genotype-guided dosing group or a control group under standard dosing. The genotype-guided dosing group had a significantly higher percentage of time in the therapeutic range than the control group (58.8% versus 53.2% [95% CI of group difference, 1.1–10.2]; P =0.01). The genotype-guided dosing group also achieved the target international normalized ratio sooner than the control group. In subgroup analyses, warfarin normal sensitivity group had an even higher percentage of time in the therapeutic range during the first 12 weeks compared with the control group (60.8% versus 48.9% [95% CI, 1.1–24.4]). The incidence of adverse events was low in both groups. Conclusions: The outcomes of genotype-guided warfarin dosing were superior to those of clinical standard dosing. These findings raise the prospect of precision warfarin treatment in China. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02211326.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
慕青的应助被稞小弟采纳,获得10
刚刚
刚刚
Forever完成签到 ,获得积分10
1秒前
1秒前
邓小雪完成签到,获得积分10
1秒前
Akim的应助被怡然的扬采纳,获得10
1秒前
三冬咚完成签到,获得积分10
2秒前
Sun完成签到,获得积分10
2秒前
科目三的应助被dan1029采纳,获得10
2秒前
大模型的应助被dan1029采纳,获得10
2秒前
xdlongchem发布了新的文献求助10
2秒前
cwb发布了新的文献求助10
2秒前
我是老大的应助被dan1029采纳,获得10
2秒前
wanci的应助被dan1029采纳,获得10
2秒前
盛盛完成签到,获得积分10
3秒前
香蕉觅云的应助被dan1029采纳,获得10
3秒前
orixero的应助被dan1029采纳,获得10
3秒前
XM驳回了我是谁的应助
3秒前
3秒前
3秒前
NexusExplorer的应助被dan1029采纳,获得10
3秒前
Akim的应助被dan1029采纳,获得10
3秒前
FashionBoy的应助被dan1029采纳,获得10
3秒前
天天快乐的应助被hupo采纳,获得10
3秒前
脑洞疼的应助被dan1029采纳,获得10
4秒前
4秒前
科研通AI65的应助被虎杖悠仁采纳,获得10
4秒前
传奇3的应助被虎杖悠仁采纳,获得10
4秒前
希望天下0贩的0的应助被Hurlee采纳,获得10
4秒前
4秒前
5秒前
科研通AI6.3的应助被Yiko采纳,获得10
5秒前
Lfy完成签到,获得积分10
5秒前
卢西奥完成签到,获得积分10
6秒前
6秒前
王彤彤发布了新的文献求助10
6秒前
6秒前
ZH完成签到 ,获得积分10
6秒前
6秒前
xpppp完成签到,获得积分10
6秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180713
求助须知:如何正确求助?哪些是违规求助? 9570752
关于积分的说明 21814119
捐赠科研通 7776960
什么是DOI,文献DOI怎么找? 3433298
关于科研通互助平台的介绍 2557579
邀请新用户注册赠送积分活动 2479287